N-hydroxy-2-methyl-2-(6,7,8,9-tetrahydro-dibenzofuran-3-sulfonylamino)-propionamide | 326499-79-0

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: N-hydroxy-2-methyl-2-(6,7,8,9-tetrahydro-dibenzofuran-3-sulfonylamino)-propionamide
• 英文别名: N-hydroxy-2-methyl-2-(6,7,8,9-tetrahydrodibenzofuran-3-ylsulfonylamino)propanamide
• CAS: 326499-79-0
• 化学式: C₁₆H₂₀N₂O₅S
• 分子量: 352.411
• InChiKey: ZJSAKAIGXUWOIN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  24
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  117
• 氢给体数：
  3
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  在 盐酸羟胺 、 碳酸氢钠 作用下， 以 四氢呋喃 、 水 为溶剂， 以58%的产率得到N-hydroxy-2-methyl-2-(6,7,8,9-tetrahydro-dibenzofuran-3-sulfonylamino)-propionamide
  参考文献：
  名称：

  Hydroxamic acid compounds useful as matrix metalloproteinase inhibitors

  摘要：

  该公式化合物用于抑制动物体内的基质金属蛋白酶酶，从而预防和治疗由结缔组织分解引起的疾病。还公开了制备这种化合物的方法，包括药物组合物，以及治疗涉及基质金属蛋白酶的疾病的方法，包括多发性硬化症、动脉粥样硬化性斑块破裂、再狭窄、主动脉瘤、心力衰竭、牙周病、角膜溃疡、烧伤、褥疮溃疡、慢性溃疡或伤口、癌症转移、肿瘤血管生成、骨质疏松症、风湿性或骨关节炎、肾脏疾病、左心室扩张，或依赖白细胞组织入侵的其他自身免疫或炎症性疾病。

  公开号：

  US06677355B1

文献信息

• HYDROXAMIC ACID COMPOUNDS USEFUL AS MATRIX METALLOPROTEINASE INHIBITORS
  申请人：Warner-Lambert Company LLC

  公开号：EP1210326B1

  公开（公告）日：2004-02-25
• US6677355B1
  申请人：——

  公开号：US6677355B1

  公开（公告）日：2004-01-13
• [EN] HYDROXAMIC ACID COMPOUNDS USEFUL AS MATRIX METALLOPROTEINASE INHIBITORS<br/>[FR] COMPOSES D'ACIDE HYDROXAMIQUE UTILES COMME INHIBITEURS DE METALLOPROTEINASES MATRICIELLES
  申请人：WARNER LAMBERT CO

  公开号：WO2001012592A2

  公开（公告）日：2001-02-22

  Compounds of formula (I), are useful for inhibiting matrix metalloproteinase enzymes in animals, and as such, prevent and treat diseases resulting from the breakdown of connective tissues. Also disclosed are methods for the preparation of such compounds, pharmaceutical compositions including the same, and methods of treating diseases in which matrix metalloproteinases are involved including multiple sclerosis, atherosclerotic plaque rupture, restenosis, aortic aneurysm, heart failure, periodontal disease, corneal ulceration, burns, decubital ulcers, chronic ulcers or wounds, cancer metastasis, tumor angiogenesis, osteoporosis, rheumatoid or osteoarthritis, renal disease, left ventricular dilation, or other autoimmune or inflammatory diseases dependent upon tissue invasion by leukocytes.
• Hydroxamic acid compounds useful as matrix metalloproteinase inhibitors
  申请人：Warner-Lambert Company

  公开号：US06677355B1

  公开（公告）日：2004-01-13

  Compounds of the formula; are useful for inhibiting matrix metalloproteinase enzymes in animals, and as such, prevent and treat diseases resulting from the breakdown of connective tissues. Also disclosed are methods for the preparation of such compounds, pharmaceutical compositions including the same, and methods of treating diseases in which matrix metalloproteinases are involved including multiple sclerosis, atherosclerotic plaque rupture, restenosis, aortic aneurysm, heart failure, periodontal disease, corneal ulceration, burns, decubital ulcers, chronic ulcers or wounds, cancer metastasis, tumor angiogenesis, osteoporosis, rheumatoid or osteoarthritis, renal disease, left ventricular dilation, or other autoimmune or inflammatory diseases dependent upon tissue invasion by leukocytes.

  该公式化合物用于抑制动物体内的基质金属蛋白酶酶，从而预防和治疗由结缔组织分解引起的疾病。还公开了制备这种化合物的方法，包括药物组合物，以及治疗涉及基质金属蛋白酶的疾病的方法，包括多发性硬化症、动脉粥样硬化性斑块破裂、再狭窄、主动脉瘤、心力衰竭、牙周病、角膜溃疡、烧伤、褥疮溃疡、慢性溃疡或伤口、癌症转移、肿瘤血管生成、骨质疏松症、风湿性或骨关节炎、肾脏疾病、左心室扩张，或依赖白细胞组织入侵的其他自身免疫或炎症性疾病。